Establishing the scalability of micro/milli-scale antibody-drug conjugate conjugation reactions

Georgina Armstrong

Establishing the scalability of micro/milli-scale antibody-drug conjugate conjugation reactions

Georgina Armstrong

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Poster

Abstract

Antibody-drug conjugates (ADCs) are complex immunotherapies requiring consistent quality assessment from early discovery. Despite the development of robust large-scalemethods, microgram to milligram scale reaction scalability is underexplored.
Here, we define this using DAR, purity, hydrophobicity, and aggregation metrics via twomodel ADCs: a trastuzumab-dansyl dye mimic (T-dansyl) and a trastuzumab-JQ1
conjugate (T-JQ1) at 0.1–1.7 mg, across two reduction states (low and high DAR targeting).

Original language	English
Publication status	Published - 9 Sept 2025
Event	16th PharmSci International Conference - Principality Stadium, Cardiff, United Kingdom Duration: 9 Sept 2025 → 11 Sept 2025 https://apsgb.co.uk/pharmsci-2025/

Conference

Conference	16th PharmSci International Conference
Abbreviated title	PharmSci 2025
Country/Territory	United Kingdom
City	Cardiff
Period	9/09/25 → 11/09/25
Internet address	https://apsgb.co.uk/pharmsci-2025/

Keywords

antibody-drug conjugates
immunotherapies

Cite this

@conference{c544ffdb79924e54983d8ff6ab9f122b,

title = "Establishing the scalability of micro/milli-scale antibody-drug conjugate conjugation reactions",

abstract = "Antibody-drug conjugates (ADCs) are complex immunotherapies requiring consistent quality assessment from early discovery. Despite the development of robust large-scalemethods, microgram to milligram scale reaction scalability is underexplored. Here, we define this using DAR, purity, hydrophobicity, and aggregation metrics via twomodel ADCs: a trastuzumab-dansyl dye mimic (T-dansyl) and a trastuzumab-JQ1 conjugate (T-JQ1) at 0.1–1.7 mg, across two reduction states (low and high DAR targeting).",

keywords = "antibody-drug conjugates, immunotherapies",

author = "Georgina Armstrong",

year = "2025",

month = sep,

day = "9",

language = "English",

note = "16th PharmSci International Conference, PharmSci 2025 ; Conference date: 09-09-2025 Through 11-09-2025",

url = "https://apsgb.co.uk/pharmsci-2025/",

}

TY - CONF

T1 - Establishing the scalability of micro/milli-scale antibody-drug conjugate conjugation reactions

AU - Armstrong, Georgina

PY - 2025/9/9

Y1 - 2025/9/9

N2 - Antibody-drug conjugates (ADCs) are complex immunotherapies requiring consistent quality assessment from early discovery. Despite the development of robust large-scalemethods, microgram to milligram scale reaction scalability is underexplored. Here, we define this using DAR, purity, hydrophobicity, and aggregation metrics via twomodel ADCs: a trastuzumab-dansyl dye mimic (T-dansyl) and a trastuzumab-JQ1 conjugate (T-JQ1) at 0.1–1.7 mg, across two reduction states (low and high DAR targeting).

AB - Antibody-drug conjugates (ADCs) are complex immunotherapies requiring consistent quality assessment from early discovery. Despite the development of robust large-scalemethods, microgram to milligram scale reaction scalability is underexplored. Here, we define this using DAR, purity, hydrophobicity, and aggregation metrics via twomodel ADCs: a trastuzumab-dansyl dye mimic (T-dansyl) and a trastuzumab-JQ1 conjugate (T-JQ1) at 0.1–1.7 mg, across two reduction states (low and high DAR targeting).

KW - antibody-drug conjugates

KW - immunotherapies

M3 - Poster

T2 - 16th PharmSci International Conference

Y2 - 9 September 2025 through 11 September 2025

ER -

Establishing the scalability of micro/milli-scale antibody-drug conjugate conjugation reactions

Abstract

Conference

Keywords

Fingerprint

Cite this